Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery

• Status: Withdrawn
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

PURPOSE: To evaluate patient adherence to cream versus tablet based local estrogen therapy by randomizing treatment modalities to determine differences in adherence to either form.

HYPOTHESIS: There is no difference in adherence to cream versus tablet based local estrogen therapy when prescribed as a 6 week course of postoperative therapy after female pelvic reconstructive surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospitals Cleveland Medical Center
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Estrogens; Estrogens, Conjugated (USP); Polyestradiol phosphate

Criteria

Inclusion Criteria:

• Patients who underwent female pelvic reconstructive surgery at University Hospitals Case Medical Center and were given postoperative local estrogen therapy.

• Patients who consented to the study.

• Postmenopausal

Exclusion Criteria:

• Patients who were not given a prescription for postoperative lower estrogen therapy despite undergoing surgery.

• Patients with contraindications to vaginal estrogen.

• Any obliterative procedures. Patients who are unable to participate in informed consent. Patients younger than 18. Non English speaking patients